APA (7th ed.) Citation

Dummer, R., Welti, M., & Ramelyte, E. (2023). The role of triple therapy and therapy sequence in treatment of BRAF-mutant metastatic melanoma. Response to overall survival with first-line atezolizumab in combination with vemurafenib and cobimetinib in BRAFV600 mutation-positive advanced melanoma (IMspire150): Second interim analysis of a multicentre, randomised, phase 3 study. BMC.

Chicago Style (17th ed.) Citation

Dummer, Reinhard, Michèle Welti, and Egle Ramelyte. The Role of Triple Therapy and Therapy Sequence in Treatment of BRAF-mutant Metastatic Melanoma. Response to Overall Survival with First-line Atezolizumab in Combination with Vemurafenib and Cobimetinib in BRAFV600 Mutation-positive Advanced Melanoma (IMspire150): Second Interim Analysis of a Multicentre, Randomised, Phase 3 Study. BMC, 2023.

MLA (9th ed.) Citation

Dummer, Reinhard, et al. The Role of Triple Therapy and Therapy Sequence in Treatment of BRAF-mutant Metastatic Melanoma. Response to Overall Survival with First-line Atezolizumab in Combination with Vemurafenib and Cobimetinib in BRAFV600 Mutation-positive Advanced Melanoma (IMspire150): Second Interim Analysis of a Multicentre, Randomised, Phase 3 Study. BMC, 2023.